- Priovant nabs first FDA approval for targeted tablet in dermatomyositisLisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with the rare autoimmune disease, setting up the drug for blockbuster status…BioSpace · 1h ago↗ source
- FDA greenlights first oral therapy for adult dermatomyositisThe U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as a treatment for adults with dermatomyositis. Dermatomyositis is a rare autoimmune condition that attacks muscle…